POLYMATERIA
25.2.2021 11:54:08 CET | Business Wire | Press release
Polymateria, who in 2020 became the first company to evidence full biodegradation of plastic in the open environment, has today open-sourced data showing that its Biotransformation technology is recyclable as well as biodegradable.
Heralding a step forward in the shift to a more circular economy, polyethylene filmcontaining Polymateria’s Biotransformation technology has been shown to meet accepted industry protocol for recyclability through independent testing.
Polymateria’s technology demonstrates that the vision of a truly circular economy is possible. An economy where materials are reused or recycled as a matter of priority while allowing any items escaping the system to return to nature without causing any harm. By uniquely time-controlling when biodegradation will start, Polymateria’s technology allows time for recycling to take place before biodegradation is triggered.
Through open-sourcing its data, Polymateria invites other companies to work together to build a truly circular economy. The company is looking forward to working with plastic manufacturers, consumer brands and recyclers to unite the value chain and bring the circular economy vision to life.
Biodegradation of material containing Polymateria’s technology is verified by the British Standard Institution’s (BSI) new PAS 9017 standard for the Biodegradation of polyolefins in an open-air terrestrial environment which was launched in late 2020. The first of its kind, the standard sets a series of stringent pass/fail criteria ensuring full biodegradation with no microplastics or ecotoxicity left behind.
The open-sourced recyclability report from Impact Solutions can be found here .
Nial Dunne, CEO of Polymateria, said:
This is a good day for all those who believe in building a circular economy.
For too long, it has been assumed that biodegradable material cannot also be recycled. Our technology is changing perceptions. Products containing our technology should be recycled as a matter of priority, but any items escaping the system will return to nature at the right time without causing any harm.
As enablers of a circular economy, we invite the industry to join the growing number of partners working with us to bring a circular economy vision to life.
Dr Christopher Wallis, Polymateria SVP of Innovations, said:
I am pleased with the technical recyclability results achieved through the independent testing conducted by Impact Solutions. With these results, we can demonstrate that material containing our technology meets current industry protocol for mechanical recycling of polyolefins.
Dr Michail Kalloudis, Director of Polymer Science at Impact Solutions, said:
Our independent research clearly demonstrates that polyethele film containing Polymateria’s Biotransfromation masterbatch is recyclable within normal mechanical recycling streams. We tested the material stringently against recycling industry protocol.
Dr Simon Hepworth, Director of Enterprise at Imperial College London said:
We are delighted to see the progress being made by Polymateria, first at the White City Incubator and now within the Translation & Innovation Hub (I-HUB), joining a range of deep tech companies and remaining part of Imperial's entrepreneurial ecosystem. As a science-focused business developing technology to address global environmental challenges, we're proud to see them flourish and to continue our role in supporting Polymateria's efforts to build a circular economy.
Technical note:
- Polyethelene film containing Polymateria’s masterbatch technology was tested by Impact Solutions, UK. The report can be accessed here .
- Recyclability was tested and proven against the Recyclass “Recyclability Assessment Protocols for PE Films ” version 1.0 published on September 6th 2018.
About Polymateria
Polymateria’s mission is to advance science to help nature deal with the plastic pollution crisis. Born from, and now based at, Imperial College London, we’re the first company in the world to prove scientifically that you can take the most likely sources of fugitive or littered plastic and return them to nature without creating microplastics, harming the natural environment or interfering with recycling streams at scale.
The British Standards Institutions’s new BSI PAS 9017 standard ensures claims of biodegradability in the open environment can be properly verified for the first time according to independent pass/fail criteria. The Standard and Polymateria's technology were recently featured in National Geographic magazine: https://www.nationalgeographic.co.uk/environment-and-conservation/2020/11/new-self-destructing-plastic-has-helped-define-a-new-british
In 2020, Puma became the first international brand to incorporate Polymateria’s technology into its shopping bags: https://www.polymateria.com/wp-content/uploads/2020/07/10663-STim_Polymateria_26072020-A.pdf
Polymateria also has a partnership with international chemical giant Clariant (now Avient) to bring the technology to South-East Asia: https://www.clariant.com/en/Corporate/News/2019/10/Clariant-and-Polymateria-launch-partnership-to-bring-new-Biotransformation-technology-to-market-in-S
Pour Les Femmes, the ethical brand founded by actor/activitist Robin Wright and designer Karen Fowler, is the first apparel brand to introduce Polyamteria’s technology into its packaging: https://pourlesfemmes.com/blogs/blog
The company is proud to be a founding signatory of HRH The Prince of Wales’ Terra Carta (Earth Charter) established under the Sutainanble Markets Initiative.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005481/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
